CD4 and neoplasm: The C57BL/6 mice bearing subcutaneous LLC or B16F10 tumor bulks were intraperitoneally injected with anti-CD8 (TIB210), anti-CD4 (GK1.5) or anti-NK1.1 (PK136) deletion mAbs respectively every 5 days from the day before the viral therapy.